Gastric Cancer – Global Clinical Trials Review, 2026

All the vital news, analysis, and commentary curated by our industry experts.

$3450

Buy Report

Published: March 30, 2026 Report Code: GDHC7339CTIDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData's clinical trial report, “Gastric Cancer – Global Clinical Trials Review, 2026" provides an overview of Gastric Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma – Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global clinical trials landscape

Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

The Report provides enrollment trends for the past five years

Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Merck & Co Inc
Bristol-Myers Squibb Co
Roche Holding AG
AstraZeneca Plc
Jiangsu Hengrui Pharmaceuticals Co Ltd
Thermo Fisher Scientific Inc
Sanofi
Eli Lilly and Co
IQVIA Holdings Inc
Pfizer Inc

Table of Contents

List of Tables

List of Figures

Report Guidance

GlobalData Clinical Trials Report Coverage

Clinical Trials by Region

Clinical Trials and Average Enrollment by Country

Top Five Countries Contributing to Clinical Trials in Asia-Pacific

Top Five Countries Contributing to Clinical Trials in Europe

Top Countries Contributing to Clinical Trials in North America

Top Five Countries Contributing to Clinical Trials in Middle East and Africa

Top Five Countries Contributing to Clinical Trials in Central and South America

Clinical Trials by G7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials

Clinical Trials by Phase in G7 Countries

Clinical Trials in G7 Countries by Trial Status

Clinical Trials by E7 Countries: Proportion of Gastric Cancer to Oncology Clinical Trials

Clinical Trials by Phase in E7 Countries

Clinical Trials in E7 Countries by Trial Status

Clinical Trials by Phase

In Progress Trials by Phase

Clinical Trials by Trial Status

Clinical Trials by End Point Status

Subjects Recruited Over a Period of Time

Clinical Trials by Sponsor Type

Prominent Sponsors

Top Companies Participating in Gastric Cancer Therapeutics Clinical Trials

Prominent Drugs

Latest Clinical Trials News on Gastric Cancer

Mar 24, 2026: First-Line Triplet Combination of Zolbetuximab, mFOLFOX6 and Nivolumab Targeting CLDN18.2 in HER2-negative, Advanced Gastric or GEJ Adenocarcinoma

Mar 17, 2026: Tonix Announces Oral Presentation and Two Poster Presentations on Preclinical Immuno-oncology Portfolio at the AACR Annual Meeting 2026

Mar 17, 2026: Henlius Debuts Preclinical Data of Its Proprietary CDH17 ADC, Showing a Differentiated Profile in GI Cancers at ADC Asia Congress 2026

Mar 16, 2026: Novabridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer

Mar 16, 2026: Avacta announces opening of Phase 1 trial for second pipeline asset, FAP-Exd a sustained-release pre|CISION exatecan peptide-drug conjugate

Feb 24, 2026: Avacta's pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Feb 24, 2026: Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma

Feb 17, 2026: NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined With Immunochemotherapy in Patients With 1L Gastric Cancer

Feb 12, 2026: CHM CDH17 Advances to Dose Level 3

Feb 09, 2026: Voluntary Announcement Completion of Subject Enrollment in Phase III Clinical Trial of Tecotabart Vedotin “CLDN18.2 ADC”

Feb 02, 2026: Imfinzi Perioperative Regimen Recommended for Approval in the EU by CHMP for Patients With Early Gastric and Gastroesophageal Cancers

Feb 02, 2026: Henlius Holds U.S. Investigator Meeting for HLX22-GC-301, a Head-to-Head Phase 3 Trial vs Standard of Care (±Pembrolizumab) in HER2+ Gastric Cancer

Jan 28, 2026: Qurebio To Present at ASCO 2026 Its Q-1802 Phase II Clinical Results

Jan 27, 2026: Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) Were Published in Annals of Oncology

Jan 16, 2026: Appclon Partner Henlius, Jpmorgan Chase, Confident That AC101 Will Become a Blockbuster as a First-Line Treatment for Gastric Cancer

Jan 14, 2026: Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer

Jan 11, 2026: Results From Neoadjuvant Studies of Henlius’ Serplulimab in Colon/Rectal Cancer Released at ASCO GI 2026

Jan 09, 2026: Henlius Accelerates Global Phase 3 Head-to-Head Development of HLX22 as First-Line Treatment for HER2-Positive Gastric Cancer

Jan 08, 2026: Asieris Enrolls First Patient in China in Phase I Clinical Trial of APL-2401 for Patients with FGFR2/3-Driven Advanced Solid Tumors

Jan 07, 2026: Study Ties Zanidatamab Combo to 32-Month Median OS in HER2+ Metastatic Gastric Cancer

Jan 06, 2026: NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer

Clinical Trial Profile Snapshots

Abbreviations

Definitions

Research Methodology

Secondary Research

About GlobalData

Disclaimer

Source

Table

List of Tables

Gastric Cancer Therapeutics, Global, Clinical Trials by Region, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2026*

Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2026*

Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*

Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*

Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2026*

Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*

Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials by Phase, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025

Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*

Figures

List of Figures

Gastric Cancer Therapeutics, Global, Clinical Trials by Region (%), 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2026*

Gastric Cancer Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2026*

Gastric Cancer Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2026*

Gastric Cancer Therapeutics Clinical Trials, North America, Top Countries (%), 2026*

Gastric Cancer Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2026*

Gastric Cancer Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2026*

Proportion of Gastric Cancer to Oncology Clinical Trials, G7 Countries (%), 2026*

Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Phase, 2026*

Gastric Cancer Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2026*

Proportion of Gastric Cancer to Oncology Clinical Trials, E7 Countries (%), 2026*

Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Phase, 2026*

Gastric Cancer Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials by Phase (%), 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials In Progress by Phase, 2026*

Gastric Cancer Therapeutics, Global, Clinical Trials by Trial Status, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, by End Point Status, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2021-2025

Gastric Cancer Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Key Sponsors, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Top Companies by Phase, 2026*

Gastric Cancer Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2026*

GlobalData Methodology

Gastric Cancer – Global Clinical Trials Review, 2026 standard reports

Currency USD

Single User

$3,450

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Gastric Cancer reports

Pharmaceuticals

New

Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…

Pharmaceuticals

New

Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Overweight and Obesity: Epidemiology Report and Forecast to 2035

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Gastric Cancer – Global Clinical Trials Review, 2026 in real time.

Access a live Gastric Cancer – Global Clinical Trials Review, 2026 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Gastric Cancer – Global Clinical Trials Review, 2026

Scope

Reasons to Buy

Table of Contents

Table

Figures

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports